Results for tag: "Polycythemia Vera Drug"

Polycythemia Vera (PV) is a rare type of chronic myeloproliferative neoplasm (MPN) that is characterized by an overproduction of red blood cells. PV is a type of Leukemia drug, and is typically treated with a combination of chemotherapy, radiation therapy, and targeted therapies. Common chemotherapy drugs used to treat PV include hydroxyurea, busulfan, and interferon. Targeted therapies, such as JAK inhibitors, are also used to reduce the production of red blood cells. Additionally, phlebotomy, or the removal of blood, is often used to reduce the number of red blood cells in the body. The Polycythemia Vera Drug market is a specialized market, with a limited number of companies offering treatments. Some of the companies in the market include Novartis, Incyte, and Gilead Sciences. Additionally, there are several smaller companies that are developing treatments for PV, such as Karyopharm Therapeutics and Constellation Pharmaceuticals. Show Less Read more